new-infographic

Protagenic Therapeutics, Inc. has created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

TCAP-1 has shown encouraging results in pre-clinical neurologic testing in anxiety and depression.

pipe

Protagenic Therapeutics has created a portfolio of five novel neuropeptides that are in stages of development and preclinical evaluation for the treatment of mood disorders.

 

The most advanced of these discoveries is based on a brain hormone, which plays a key role in regulating depression, anxiety and other stress-related disorders. The novel neuropeptides also have potential applications in many other areas including in the field of neuroprotection and neurodengerative conditions.

 A plethora of clinical indications